Nathan Sadeghi-Nejad

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Recent Articles By The Author

Onyx Pharma: An Underdog Worth Buying

Onyx Pharma: An Underdog Worth Buying

The unexpected approval of a new multiple myeloma drug could be a big upside surprise for Onyx Pharma shares.

Verastem and the Broken Wall Street Research Model

Verastem and the Broken Wall Street Research Model

Verastem is a buy only because sell-side analysts are afraid to anger their investment banking overlords.

Seattle Genetics: A Cancer Niche Too Small

Seattle Genetics: A Cancer Niche Too Small

An investor explains the short thesis for Seattle Genetics and its cancer drug Adcetris.

Clovis Oncology: Like the Story, Not the Stock

Clovis Oncology: Like the Story, Not the Stock

An investor finds few reasons to buy three pancreatic cancer drug stocks -- Clovis, Celgene and Threshold Pharma.

The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results

The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results

The amyloid beta hypothesis doesn't explain Alzheimer's, which leaves Elan and its partners in trouble.

Gilead, Vertex and the Mystery of Missing Hep C Patients

Gilead, Vertex and the Mystery of Missing Hep C Patients

Finding treatable Hep C patients will be harder than expected, so buying into Gilead's current valuation may not be wise.

The Curse of Amylin's Diabetes Drug Approval

The Curse of Amylin's Diabetes Drug Approval

Bydureon's once-weekly convenience isn't enough to turn Amylin's new diabetes drug into a commercial success.